Tumor-shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organs

Tumor-shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organs

ObjectiveThis study aimed to determine and compare the tumor shrinkage rate and its durability by enfortumab vedotin treatment between primary urothelial carcinoma and metastatic organs.MethodsWe retrospectively evaluated the tumor shrinkage rate in 39 Japanese patients treated with enfortumab vedot...

Full description

Saved in:
Bibliographic Details
Main Authors: Daiki Ikarashi, Tatsuya Kawamura, Keita Ogasawara, Yumeka Arakawa, Arisa Machida, Ayato Ito, Ei Shiomi, Shigekatsu Maekawa, Renpei Kato, Mitsugu Kanehira, Jun Sugimura, Wataru Obara
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Oncology
Subjects:
durability
enfortumab vedotin
primary
metastatic organ
tumor shrinkage
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1493922/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1493922/full

Similar Items